Decompensation of Chronic Heart Failure Associated With Pregabalin in Patients With Neuropathic Pain

Journal of Cardiac Failure

Volumn 13, Issue 3, 2007, Pages 227-229

  Murphy, Niamh ^a   Mockler, Mary ^a   Ryder, Mary ^a   Ledwidge, Mark ^a   McDonald, Ken ^a  

^a ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ATORVASTATIN; BISOPROLOL; BUMETANIDE; CARVEDILOL; DIGOXIN; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPLERENONE; FUROSEMIDE; GLYCERYL TRINITRATE; INSULIN; LANSOPRAZOLE; LOSARTAN; METFORMIN; METOPROLOL; NICORANDIL; ORAL ANTIDIABETIC AGENT; PERINDOPRIL; PRAVASTATIN; PREGABALIN; WARFARIN;

ADULT; AGED; ANGINA PECTORIS; ARTICLE; CASE REPORT; CONGESTIVE CARDIOMYOPATHY; DIABETES MELLITUS; DRUG DOSE INCREASE; DRUG WITHDRAWAL; HEART FAILURE; HEART LEFT VENTRICLE FUNCTION; HUMAN; ISCHEMIC HEART DISEASE; MALE; NEUROPATHIC PAIN; PRIORITY JOURNAL;

AGED; ANTICONVULSANTS; GAMMA-AMINOBUTYRIC ACID; HEART FAILURE, CONGESTIVE; HUMANS; MALE; MIDDLE AGED; NEURALGIA; TREATMENT OUTCOME;

EID: 34247175277     PISSN: 10719164     EISSN: 15328414     Source Type: Journal    
DOI: 10.1016/j.cardfail.2006.11.006     Document Type: Article

References (11)

1. O'Hanlon R, O'Shea P, Ledwidge M, et al. The biological variability of B-type natriuretic peptide and N-Terminal pro-B-type natriuretic peptide in stable heart failure patients. J Card Fail. In press.
2. Lewin J., Ledwidge M., O'Loughlin C., McNally C., and McDonald K. Clinical deterioration in established heart failure: What is the value of BNP and weight gain in aiding diagnosis?. Eur J Heart Failure 7 (2005) 953-957
3. European Medicines Agency. EPARs for authorised medicinal products for human use. Available from: http://www.emea.eu.int/humandocs/Humans/EPAR/lyrica/lyrica.htm. Accessed March 2, 2007.
4. US Food and Drug Administration. Lyrica Cv. Available from: http://www.fda.gov/cder/foi/label/2006/021446s002s003lbl.pdf. Accessed March 2, 2007.
5. In: Brunton L., Lazo J., and Parker K. (Eds). Goodman & Gilman's the pharmacological basis of therapeutics. 11th ed. (2006), McGraw Hill, New York
6. Bian F., Li Z., Offord J., Davis M.D., McCormick J., Taylor C.P., et al. Calcium channel alpha2-delta type 1 subunit is the major binding protein for pregabalin in neocortex, hippocampus, amygdala, and spinal cord: an ex vivo autoradiographic study in alpha2-delta type 1 genetically modified mice. Brain Res 1075 (2006) 68-80
7. Guay D.R. Pregabalin in neuropathic pain: a more "pharmaceutically elegant" gabapentin?. Am J Geriatr Pharmacother 3 (2005) 274-287
8. Fink K., Dooley D.J., Meder W.P., Suman-Chauhan N., Duffy S., Clusmann H., et al. Inhibition of neuronal Ca(2+) influx by gabapentin and pregabalin in the human neocortex. Neuropharmacology 42 (2002) 229-236
9. Sills G.J. The mechanisms of action of gabapentin and pregabalin. Curr Opin Pharmacol 6 (2006) 108-113
10. Gao B., Sekido Y., Maximov A., Saad M., Forgacs E., Latif F., et al. Functional properties of a new voltage-dependent calcium channel alpha(2)delta auxiliary subunit gene (CACNA2D2). J Biol Chem 275 (2000) 12237-12242
11. Stefani A., Spadoni F., Giacomini P., Lavaroni F., and Bernardi G. The effects of gabapentin on different ligand- and voltage-gated currents in isolated cortical neurons. Epilepsy Res 43 (2001) 239-248